R ecent advances in immunosuppressive drug therapy and surgical techniques have significantly improved transplantation outcomes for patients with severe end-stage organ failure. Consequently, the waiting list for allografts from cadaveric donors, the largest source of organs for transplantation, has been steadily increasing (1) . More patients in the United States are waiting for organ transplants now than at any time in the past; Ͼ90,000 patients are currently registered through the United Network for Organ Sharing (UNOS) (http:// www.optn.org). Increased demand for organs has prompted consideration of donor criteria previously deemed less suitableso-called extended or expanded donor criteria (2, 3) .
Traditional and expanded criteria recognize the potential for unfavorable organ conditions that predispose the organ to graft failure in the recipient. Unfavorable organs may result from donor age, body size or sex mismatching, history of smoking, and comorbid conditions such as coronary or peripheral vascular disease, diabetes, and renal failure. In addition, hormonal, cardiovascular, and endocrine changes during the evolution of brain death may further compromise potentially transplantable organs and risk delayed graft function or failure (4, 5) .
Brain death often causes severe derangements in regional perfusion, (6) due to initial increased sympathetic neural outflow (7) followed by subsequent autonomic collapse (8) , and is also associated with a wide array of immunologic changes (9, 10) . Through numerous mechanisms, brain death is associated with a massive release of proinflammatory cytokines, detectable both in blood (10 -12) and transplantable organs (13, 14) . Furthermore, this increased inflammatory response has been associated with poor allograft function, particularly in the heart (15) (16) (17) (18) . Although controversial, substitution of hormones antagoniz-Background: Inflammatory cytokines occur in the circulation and in the tissues after brain death and have been associated with dysfunction of donor organs before and after transplantation.
Objective: To determine the feasibility of removing cytokines using a hemoadsorption device.
Design: Two-center, randomized, open-label, feasibility study in which brain-dead subjects were randomized to two treatment groups.
Setting: Two U.S. academic hospitals.
Participants: Eight brain-dead subjects deemed unsuitable for organ donation by respective organ procurement organizations.
Main Outcome Measures: After obtaining consent from families, subjects were treated with hemoadsorption for 4 hrs using CytoSorb. Effects on cytokines (tumor necrosis factor, interleukin [IL]-6, and IL-10) were assessed both across the device and in the plasma over time. Feasibility for cytokine removal was assessed using objective criteria.
Results: Cytokine removal across the CytoSorb device ranged from 4% to 30% and was not significantly different from 1 hr to 4 hrs. Overall removal was greatest for IL-6, 28% (p ‫؍‬ .006), and least for tumor necrosis factor, 8.5% (p ‫؍‬ .13). Plasma concentrations of both IL-6 and tumor necrosis factor, but not IL-10, were significantly reduced after the first hour of therapy; mean differences were ؊13% ؎ 7% for IL-6 (p ‫؍‬ .039), ؊23% ؎ 9% for tumor necrosis factor (p ‫؍‬ .02), and ؊2% ؎ 7% of IL-10 (p ‫؍‬ 23). However, plasma concentrations for all three cytokines increased over time and were above baseline by the end of the intervention. No adverse effects of therapy were observed. However, removal of cortisol and triiodothyronine was similar to removal of cytokines.
Conclusions: Hemoadsorption for removal of cytokines in brain-dead subjects is feasible. Evaluation of possible clinical benefit will require controlled trials in actual donors. However, the significant capacity for cytokine removal and absence of adverse events suggest that such trials are warranted. (Crit Care Med 2008; 36:268-272) KEY WORDS: organ donation; brain death; cytokines; inflammation mediators; interleukin-6; interleukin-10; tumor necrosis factor; blood purification; hemoadsorption; sepsis; organ procurement; transplantation ing proinflammatory cytokine effects, including corticosteroids (19) , triiodothyronine (20 -22) , and arginine vasopressin (23), may be beneficial in maintaining donor heart function after brain death. However, these drugs have other potentially important effects on organ function, making a causal connection between cytokine antagonism and outcome difficult. Immune modulating drugs also have numerous side effects and may, therefore, further injure target organs.
Unlike drugs, blood purification using hemofiltration or hemoadsorption may be an ideal method to modulate the immune response in brain-dead donors (24) . We have previously tested CytoSorb, an adsorption-based cytokine removal device, in vitro (25) and in animals with sepsis (26) and have demonstrated significant cytokine removal. We conducted the present pilot study to test the feasibility and effect of using CytoSorb in brain-dead organ donors. Given the preliminary nature of this investigation, we chose to study brain-dead subjects who were not suitable for organ donation.
METHODS
Sites and Subjects. We enrolled subjects at two sites, the University of Pittsburgh Medical Center, Pittsburgh, PA, and Memorial Hermann Hospital, Houston, TX. Study inclusion criteria were: fulfilled brain-death criteria per hospital policy and deemed not suitable for organ donation by the local organ procurement organization. Exclusion criteria were: age of Ͻ16 yrs, inability to obtain informed consent from subject's authorized representative, enrolled in experimental protocols in which cytokines are the therapeutic targets (e.g., anti-tumor necrosis factor [TNF] antibodies), receiving chemotherapy or diagnosed with any disease state (e.g., AIDS) that has produced leukopenia (white blood cell count of Ͻ2), or receiving antileukocyte drugs. Organ procurement organizations taking part in the study were Center for Organ Recovery and Education (CORE), Pittsburgh, PA, and Life-Gift, Houston, TX. We obtained approval from the University of Pittsburgh Committee for Oversight of Research Involving the Dead (CO-RID) and from the University of Texas Health Science Center at Houston Committee for the Protection of Human Subjects. Written informed consent was obtained from family members before enrollment.
Study Procedures. After enrollment, we randomized all subjects to receive 4 hrs of hemoadsorption using either a 300-mL or 500-mL CytoSorb cartridge (MedaSorb Technologies, Princeton, NJ). The active component of the CytoSorb device consists of adsorbent polymer beads composed of porous polymerized divinylbenzene. These beads have pores that are appropriately sized to remove cytokines. The polymer beads are encased in a polycarbonate canister commonly used in commercially available dialyzers. Randomization was accomplished using sequentially numbered, sealed envelopes. Hemoadsorption was provided in an open-label, unblinded fashion. We gathered detailed baseline and sequential clinical information using bedside assessments and medical record abstraction. We recorded data in a case report form, which was double-key entered into a database. We obtained blood for cytokine assays immediately after enrollment and at each hour of treatment. At the end of hours 1 and 4, we also obtained blood from the inlet and outlet ports of the CytoSorb device. All research and clinical laboratory staff involved in data and sample collection were trained and audited throughout the study. Subjects were enrolled between July 2004 and September 2005.
Hemoadsorption Procedure. We primed the CytoSorb cartridge at the bedside using 2 L of 0.9% saline. Vascular access was accomplished using a standard dialysis catheter (Arrow International, Reading, PA) placed in the femoral vein, and we connected the catheter to the CytoSorb device using standard dialysis lines. Blood was pumped through the device using a BM-11 blood pump (Baxter Healthcare, Deerfield, IL). We set initial blood flow at 150 mL/min. Blood flow was adjusted between 120 and 180 mL/min, depending on access pressures. We used an infusion of unfractionated heparin for anticoagulation, adjusting the infusion to maintain an activated coagulation time between 141 and 180 secs.
Cytokine Assays. We measured circulating levels of TNF and interleukin (IL)-6 as markers of the proinflammatory cytokine response and IL-10 as a marker of the anti-inflammatory cytokine response. Blood samples were drawn at time 0 and hourly for 4 hrs. We also obtained blood from the inlet and outlet ports of the device at the end of hours 1 and 4. Blood samples were drawn into pyrogen-free vials containing heparin or no additive. Plasma was separated by centrifugation and frozen (Ϫ80°C). We measured TNF, IL-6, and IL-10 by chemiluminescent immunoassay using an automated analyzer (IMMULITE, Diagnostic Products, Los Angeles, CA), thawing samples only once before assay.
Complement Assays. We measured complement fractions C3a-desArg and SC5b-9. Each blood sample was collected into pyrogenfree disodium or dipotassium EDTA collection tubes, placed on ice, and processed within 30 mins. Plasma was separated into six sterile 0.5-mL cryovials and frozen at Ϫ80°C. Commercially available enzyme immunoassay (EIA) kits were used for complement assays (Quidel, San Diego, CA).
Safety Measures. Possible complications of the hemoadsorption process were evaluated by serial measurements of blood components that were of the molecular size likely to be removed by the CytoSorb device. These included triiodothyronine and cortisol (measured in blood samples before and after circulation through the cartridge) and glucose, albumin, platelets, white blood cell count, and hemoglobin concentrations before and after hemoadsorption. We measured complement (C3a-desArg and SC5b-9) at time points 1, 2, 3, and 7 to evaluate biocompatibility. Clinical tolerance was evaluated by measures of cardiovascular and lung function (mean arterial pressure, vasopressor requirements, and PaO 2 / FIO 2 ratio).
Calculations, Imputations, and Statistical Analysis. We calculated solute removal by comparing precartridge and postcartridge concentrations (from inlet and outlet samples) and expressed the result as a percentage of the precartridge concentration. Concentrations of all substances measured were expressed as the percentage difference from their baseline concentrations before hemoadsorption. Two subjects had no detectable baseline concentrations of IL-10 and were excluded from analysis of solute removal, but they were included for comparisons over time by setting baseline concentrations at the lower limit of assay detection (5 pg/mL).
Statistical analyses were performed using MedCalc software (Mariakerke, Belgium). We compared solute concentrations using Wilcoxon's test for paired samples and set alpha at p Ͻ .05. Mean values are reported Ϯ standard error. Given the low overall enrollment, no attempt was made to compare 300-mL to 500-mL cartridges with respect to efficacy. However, we describe differences where apparent.
RESULTS
Enrollment and Randomization. Although our target enrollment was 24 subjects in 12 months, we were only able to enroll eight subjects in 14 months. Lower than expected enrollment was not a function of refusal of informed consent. Indeed, only two additional patients met inclusion criteria during the enrollment period. Instead, a lower than expected number of subjects for whom death was declared by brain death criteria were deemed not suitable for organ donation. This discrepancy between anticipated and actual enrollment apparently was due to an aggressive use of "extended donor criteria" (2, 3) and the clinical practice of early withdrawal of care before brain death when donation was refused or deemed inappropriate. Of the eight subjects enrolled, three were randomized to the 500-mL and five to the 300-mL cartridge.
Feasibility. Hemoadsorption was feasible in these brain-dead subjects and could be provided safely. Demographic data and clinical and laboratory data before and after treatment are shown in Table 1 . One dialysis catheter clotted during treatment, but there were no other adverse technical events. Platelets decreased significantly during the course of therapy: 36.6% with the 500-mL device and 21% with the 300-mL device. However, there was no direct change in platelets across the device when measured at the first and fourth hours, and no bleeding or decline in the hemoglobin concentration was observed. White blood cell counts and glucose and albumin concentrations did not change. The results of complement activation studies are shown in Table 2 ; no evidence of complement activation was observed.
Cytokine Removal. Cytokine removal was assessed by examining the concentration of mediators in blood before and after the cartridge and by measuring mediator concentrations over time. Precartridge and postcartridge concentrations after 1 and 4 hrs of treatment are shown in Table 3 . Cytokine removal ranged from 4% to 30% across the device and the rate of removal was not significantly different between 1 hr and 4 hrs. Overall removal was greatest for IL-6 (28%, p ϭ .006) and least for TNF (8.5%, p ϭ .13).
After a single hour of therapy, plasma concentrations of both IL-6 and TNF, but not IL-10, were significantly reduced ( Fig. 1 ). Mean differences were Ϫ13% Ϯ 7% for IL-6 (p ϭ .039), Ϫ23% Ϯ 9% for TNF (p ϭ .02), and Ϫ2% Ϯ 7% for IL-10 (p ϭ .23). However, over time, all three cytokines increased and plasma concentrations were above baseline by the end of hemoadsorption.
Cortisol and Triiodothyronine. We also measured serum cortisol and triiodothyronine precartridge and postcartridge. Levels of triiodothyronine were below detection for all but one subject, but for this subject, the removal was 20%. Cortisol removal is shown in Table 3 . Removal was greatest at time 1 (48.8%) compared with time 4 (16.1%).
DISCUSSION
There is currently a critical imbalance between organs available for donation and their need. In 2006, approximately 7,400 organ donors provided just over 26,000 organs, or approximately 3.5 organs per donor. By increasing the number of organs recovered per donor by just 0.5, it would be possible to increase the number of organs available for transplant by 14%. A small number of additional organs might also be recoverable from donors who would otherwise be judged unsuitable due to severe shock or organ dysfunction. Finally, as the organ donor pool is expanded to include less ideal donors, techniques to reduce organ dysfunction will become increasingly important.
To the extent that circulating inflammatory mediators contribute to organ dysfunction both during the evolution of brain death and after brain death and could render organs unacceptable for transplantation, hemoadsorption is an intriguing therapeutic possibility. Our results indicate that a short course of hemoadsorption is feasible and capable of cytokine removal when applied to braindead subjects.
Clinical effectiveness in terms of reducing inflammatory cytokine levels in the blood and tissue can only be hinted at, given the uncontrolled design of this feasibility study. However, substantial removal of IL-6 and TNF was observed. Although TNF and IL-6 increased after the TNF, tumor necrosis factor; IL, interleukin; pre, values derived from samples taken from the inlet port of the device; post, values derived from samples taken from the outlet port of the device. a p values (Wilcoxon's test) are for the comparison of plasma concentrations taken at the inlet (pre) and the outlet (post) of the device, treating time points 1 and 4 together. first hour (indicating ongoing production), the rate of increase in both cytokines was less than expected from untreated cases (10 -12) . However, these published cases may have substantially different circumstances than those encountered in our study and direct comparison is not possible. The severity of injury or rate of brain death could affect cytokine levels, and thus, trials in actual donors will be required to examine effectiveness. Importantly, there was no evidence of saturation, as the device seemed to perform equally well at time points 1 and 4 (Table 3 ). However, we observed no improvement in hemodynamics or organ function (Table 1 ) over time in these subjects. Few studies have reported IL-10 levels in the plasma of brain-dead humans. Our data indicate a very low level of activation of this anti-inflammatory cytokine, and these low levels were not greatly affected by hemoadsorption.
The association between the physiologic changes that occur during the evolution of brain death and injury to potentially transplantable organs seems strong. However the individual contributions and relative importance to organ failure made by such factors as circulating cytokines, increased catecholamines, altered endocrine hormones, and changes in vascular tone remain poorly defined (6, (27) (28) (29) (30) (31) . Data from animal experiments and human observation have shown that rapid increases in intracranial pressure up-regulates various lymphocyte-and macrophage-derived cytokines (11) . In addition, increased ex-pression of proinflammatory cytokines has been demonstrated in the hearts of braindead animals (13) , and isolated elevations of plasma IL-6 have been demonstrated in brain-dead donors (12) . Stangl et al. (10) showed significantly elevated levels of TNF, IL-6, IL-8, and IL-2 receptor levels in the blood of brain-dead organ donors compared with living related donors. In a more recent study, Plenz et al. (14) demonstrated significant activation of IL-6/IL-6 receptor system in donor hearts compared with endomyocardial biopsies obtained from control patients. Thus, in brain-dead donors, both the plasma levels of IL-6 and the responsiveness to IL-6 are increased simultaneously (via increased expression of IL-6 receptor system). It is plausible, therefore, that the reduced organ function and viability seen in organs explanted from braindead donors is in part due to the inflammatory response seen during the evolution of and after brain death (14 -18) . Alternatively, cytokines may be only markers of organ injury rather than mediators. In this case, blood purification may only serve to remove the cytokines but not influence organ function.
Recently, we have demonstrated that hemoadsorption using the CytoSorb device effectively removes multiple inflammatory mediators and improves shortterm survival in animal models of sepsis (26) . Our results in this study suggest similar effects on plasma cytokines in human brain-dead subjects. However, overall changes in plasma cytokine concentrations were modest, and whether these effects will be sufficient to improve clinical outcomes, such as short-term organ function, is unknown. Our results show that this procedure is feasible, and with the limited measures used to assess outcome, no adverse consequences were observed. These results form the theoretical basis for conducting additional studies after brain death, perhaps in actual donors. Subsequent studies will expand the number of normal plasma components and compounds monitored to determine whether any are excessively removed during hemoadsorption and require supplementation before organ removal. For example, removal of triiodothyronine and cortisol might require increased supplementation over current practice. In addition, further attention will be directed toward physiologic markers of organ function for lung, heart, liver, and kidney. The observed decrement in platelets is not clearly attributable to hemoadsorption, and the cross-cartridge platelet counts were equal and were not associated with clinical bleeding in this study. Our study is one of a very small number of trials enrolling brain-dead human subjects, and some discussion of the feasibility, ethics, and suitability of this population seems warranted. First, enrollment of these brain-dead subjects did not seem to produce an additional burden to families. Refusal rates were surprisingly low, and most families seemed interested in this option, even when they refused actual donation. Conversely, the number of subjects who qualified for our study was lower than expected. Formal brain death evaluation seems to be unusual in patients who are deemed not suitable for organ donation, and thus, few families were presented with the option for research. Finally, brain-dead subjects who are deemed not suitable for organ donation may not be representative of actual donors, and thus, generalizability of our results to this population is limited. For purposes of evaluating feasibility, this may not have posed a problem. However, this population may be less suitable for examining efficacy of interventions. This raises a potential concern because early interventional studies in actual donors are logistically challenging and pose unique ethical considerations.
CONCLUSION
Hemoadsorption after brain death can remove cytokines from the circulation. The significant capacity for cytokine re- moval may be of substantial benefit in attenuating the inflammatory response associated with brain death. Evaluation of clinical effectiveness of this intervention on improving organ function will require controlled trials involving actual donors.
